Selective targets for arousal-modifying drugs: Implications for the treatment of sleep disorders

Drug Discovery Today

Volumn 19, Issue 5, 2014, Pages 701-708

  Szabadi, Elemer ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; MELATONIN RECEPTOR AGONIST; OREXIN RECEPTOR; SEROTONIN ANTAGONIST;

AROUSAL; DAYTIME SOMNOLENCE; DRUG SELECTIVITY; DRUG TARGETING; INSOMNIA; REVIEW; SEROTONINERGIC SYSTEM; SLEEP DISORDER; SUPRACHIASMATIC NUCLEUS; ANIMAL; DRUG DELIVERY SYSTEM; DRUG EFFECTS; HUMAN; METABOLISM; NERVE CELL NETWORK; PHYSIOLOGY; PINEAL BODY; PROCEDURES; SLEEP DISORDERS; TREATMENT OUTCOME; WAKEFULNESS;

ANIMALS; AROUSAL; DRUG DELIVERY SYSTEMS; HISTAMINE ANTAGONISTS; HUMANS; NERVE NET; PINEAL GLAND; SLEEP DISORDERS; TREATMENT OUTCOME; WAKEFULNESS;

EID: 84901505451     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2014.01.001     Document Type: Review

References (85)

1. A.J. Mitchell Neuropsychiatry and Behavioural Neurology Explained 2004 Saunders
2. American Academy of Sleep Medicine International Classification of Sleep Disorders: Diagnostic and Coding Manuel 2nd edn 2005 American Academy of Sleep Medicine
3. M.J. Aminoff Electroencephalography: general principles and clinical applications M.J. Aminoff, Electrodiagnosis in Clinical Neurology 3rd edn 1992 Churchill-Livingstone 41 91
4. D.N. Franz Drugs acting on the central nervous system: introduction L.S. Goodman, A. Gilman, The Pharmacological Basis of Therapeutics 5th edn 1975 Macmillan 47 53
5. P. Fort et al. Alternating vigilance states: new insights regarding neuronal networks and mechanisms Eur. J. Neurosci. 29 2009 1741 1753
6. B.E. Jones From waking to sleeping: neuronal and chemical substrates Trends Pharmacol. Sci. 26 2005 578 586
7. J-S. Lin et al. The waking brain: an update Cell. Mol. Life Sci. 68 2011 2499 2512
8. E. Szabadi Drugs for sleep disorders: mechanisms and therapeutic prospects Br. J. Clin. Pharmacol. 61 2006 761 766
9. H.L. Haas, and J-S. Lin Waking with the hypothalamus Pflugers. Arch. Eur. J. Physiol. 463 2012 31 42
10. J.M. Monti, and H. Jantos The roles of dopamine and serotonin, and their receptors, in regulating sleep and waking Prog. Brain Res. 172 2008 625 646
11. P.M. Fuller et al. The pontine REM switch: past and present J. Physiol. 584 2007 735 741
12. R.W. McCarley Neurobiology of REM and NREM sleep Sleep Med. 8 2007 302 330
13. J. Lu et al. A putative flip-flop switch for control of REM sleep Nature 441 2006 589 594
14. P.H. Luppi et al. Brainstem mechanisms of paradoxical (REM) sleep generation Pflugers Arch. 463 2012 43 52
15. C.B. Saper et al. Sleep state switching Neuron 68 2010 1023 1042
16. R.E. Brown et al. Control of sleep and wakefulness Physiol. Rev. 92 2012 1087 1187
17. P. Fuller et al. Reassessment of the structural basis of the ascending arousal system J. Comp. Neurol. 519 2011 933 956
18. J.C. Zant et al. Histamine release in the basal forebrain mediates cortical activation through cholinergic neurons J. Neurosci. 32 2012 13244 13254
19. Z. Lelkes et al. Cholinergic basal forebrain structures are involved in the mediation of the arousal effect of noradrenaline J. Sleep Res. 22 2013 721 726
20. O.K. Hassani et al. Discharge profiles of identified GABAergic in comparison to cholinergic and putative glutamatergic basal forebrain neurons across the sleep-wake cycle J. Neurosci. 29 2009 11828 11840
21. E. Szabadi Functional neuroanatomy of the central noradrenergic system J. Psychopharmacol. 27 2013 659 693
22. E.R. Samuels, and E. Szabadi Functional neuroanatomy of the noradrenergic locus coeruleus: its roles in the regulation of arousal and autonomic function, Part I: principles of functional organisation Curr. Neuropharmacol. 6 2008 235 253
23. J.M. Monti Serotonin control of sleep-wake behaviour Sleep Med. Rev. 15 2011 269 281
24. G. Niepel et al. Association of a deficit of arousal with fatigue in multiple sclerosis: effect of modafinil Neuropharmacology 664 2013 380 388
25. C.B. Saper et al. Hypothalamic regulation of sleep and circadian rhythms Nature 437 2005 1257 1263
26. 2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways J. Pharmacol. Exp. Ther. 306 2003 954 964
27. O.K. Hassani et al. Melanin-concentrating hormone neurons discharge in a reciprocal manner to orexin neurons across the sleep-wake cycle Proc. Natl. Acad. Sci. U. S. A. 106 2009 2418 2422
28. J.M. Monti et al. Melanin-concentrating hormone control of sleep-wake behavior Sleep Med. Rev. 17 2013 293 298
29. T. Sakurai The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness Nat. Rev. Neurosci. 8 2007 171 181
30. E.R. Samuels, and E. Szabadi Functional neuroanatomy of the noradrenergic locus coeruleus: its roles in the regulation of arousal and autonomic function, Part II: physiological and pharmacological manipulations and pathological alterations of locus coeruleus activity in humans Curr. Neuropharmacol. 6 2008 254 285
31. A. Kalsbeek et al. Melatonin sees the light: blocking GABA-ergic transmission in the paraventricular nucleus induces daytime secretion of melatonin Eur. J. Neurosci. 12 2000 3146 3154
32. A. Kalsbeek et al. SCN outputs and the hypothalamic balance of life J. Biol. Rhythms 21 2006 458 469
33. R.E. Mistlberger Circadian regulation of sleep in mammals: role of the suprachiasmatic nucleus Brain Res. Rev. 49 2005 429 454
34. S. Deurveilher et al. Indirect projections from the suprachiasmatic nucleus to the ventrolateral preoptic nucleus: a dual tract-tracing study in rat Eur. J. Neurosci. 16 2002 1195 1213
35. S. Deurveilher, and K. Semba Indirect projections from the suprachiasmatic nucleus to major arousal-promoting cell groups in rat: implications for the circadian control of behavioural state Neuroscience 130 2005 165 183
36. J.J. Gooley et al. A broad role for melanopsin in nonvisual photoreception J. Neurosci. 23 2003 7093 7106
37. P.M. Fuller et al. Neurobiology of the sleep-wake cycle: sleep architecture, circadian regulation, and regulatory feedback J. Biol. Rhythms 21 2006 482 493
38. G. Aston-Jones Brain structures and receptors involved in alertness Sleep Med. 6 Suppl. 1 2005 3 7
39. G. Vandewalle et al. Brain responses to violet, blue and green monochromatic light exposures in humans: prominent role of blue light and the brainstem PLoS ONE 11 2007 e1247
40. C. Cajochen Alerting effects of light Sleep Med. Rev. 11 2007 453 464
41. W. Adidharma et al. Orexinergic signaling mediates light-induced neuronal activation in the dorsal raphe nucleus Neuroscience 220 2012 201 207
42. S.R. Pandi-Perumal et al. Melatonin - nature's most versatile biological signal? FEBS J. 273 2006 2813 2838
43. R. Hardeland Melatonin in aging and disease - multiple consequences of reduced secretion, options and limits of treatment Aging Dis. 3 2012 194 225
44. I.V. Zhdanova Melatonin as a hypnotic: pro Sleep Med. Rev. 9 2005 51 65
45. D. Dawson, and S.M. Armstrong Chronobiotics - drugs that shift rhythms Pharmacol. Ther. 69 1996 15 36
46. E.R. Dodson, and P.C. Zee Therapeutics for circadian rhythm sleep disorders Sleep Med. Clin. 5 2010 701 715
47. T.E. Scammell, and C.J. Winrow Orexin receptors: pharmacology and therapeutic opportunities Annu. Rev. Pharmacol. Toxicol. 51 2011 243 266
48. A. Proctor, and M.T. Bianchi Clinical pharmacology in sleep medicine ISRN Pharmacol. 2012 2012 914168
49. M. Lader Benzodiazepines revisited - will we ever learn? Addiction 106 2011 2086 2109
50. A receptor modulators as hypnotics J. Psychopharmacol. 24 2010 1601 1612
51. K. Sonka, and M. Susta Diagnosis and management of central hypersomnias Ther. Adv. Neurol. Disord. 5 2012 297 305
52. L. Ferini Strambi A need for new treatments in narcolepsy Lancet Neurol. 12 2013 1039 1040
53. K. Ohno, and T. Sakurai Orexin neuronal circuitry: role in the regulation of sleep and wakefulness Front. Neuroendocrinol. 29 2008 70 87
54. H.S. Gompf, and G. Aston-Jones Role of orexin input in the diurnal rhythm of locus coeruleus impulse activity Brain Res. 1224 2008 43 52
55. Y. Oka et al. Narcolepsy without cataplexy: 2 subtypes based on CSF hypocretin-1/orexin-A findings Sleep 29 2006 1439 1443
56. O. Andlauer et al. Predictors of hypocretin (orexin) deficiency in narcolepsy without cataplexy Sleep 35 2012 1247 1255
57. M. Mieda et al. Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice Proc. Natl. Acad. Sci. U. S. A. 101 2004 4649 4654
58. C. Dugovic et al. Blockade of orexin-1 receptors attenuates orexin-2 receptor antagonism-induced sleep promotion in the rat J. Pharmacol. Exp. Ther. 330 2009 142 151
59. S.R. Morairty et al. Dual hypocretin receptor antagonism is more effective for sleep promotion than antagonism of either receptor alone PLoS ONE 7 2012 e39131
60. C. Brisbare-Roch et al. Promotion of sleep by targeting the orexin system in rats, dogs and humans Nat. Med. 13 2007 150 155
61. Hoever et al. Orexin receptor antagonism, a new sleep-enabling paradigm: a proof-of-concept clinical trial Clin. Pharmacol. Ther. 91 2012 975 985
62. W.J. Herring et al. Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant Neurology 79 2012 2265 2274
63. H. Sun et al. Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men Sleep 36 2013 259 267
64. P. Bettica et al. The orexin antagonist SB-649868 promotes and maintains sleep in men with primary insomnia Sleep 35 2012 1097 1104
65. P. Bettica et al. Phase I studies on the safety, tolerability, pharmacokinetics and pharmacodynamics of SB-649868, a novel dual orexin receptor antagonist J. Psychopharmacol. 26 2012 1058 1070
66. M. Tafti Reply to 'Promotion of sleep by targeting the orexin system in rats, dogs and humans' Nat. Med. 13 2007 525 526
67. G.M. Mang et al. The dual orexin receptor antagonist almorexan induces sleep and decreases orexin-induced locomotion by blocking orexin 2 receptors Sleep 35 2012 1625 1635
68. S.W. Black et al. Almorexant promotes sleep and exacerbates cataplexy in a murine model of narcolepsy Sleep 36 2013 325 336
69. N. Santana et al. Expression of α1-adrenergic receptors in rat prefrontal cortex: cellular co-localization with 5-HT2A receptors Int. J. Neuropsychopharmacol. 16 2013 1139 1151
70. K.E. Vanover, and R.E. Davis Role of 5-HT2A receptor antagonists in the treatment of insomnia Nat. Sci. Sleep 2 2010 139 150
71. A. Fares Night-time exogenous melatonin administration may be a beneficial treatment for sleeping disorders in beta blocker patients J. Cardiovasc. Dis. Res. 2 2011 153 155
72. A. Lerchl, and R.J. Reiter Treatment of sleep disorders with melatonin BMJ 345 2012 e6968
73. 2 receptor agonist: a novel therapeutic drug for sleep disorders CNS Neurosci. Ther. 15 2009 32 51
74. V. Srinivasan et al. Melatonergic drugs for therapeutic use in insomnia and sleep disturbances of mood disorders CNS Neurol. Disord. Drug Targets 11 2012 180 189
75. M.M. Thakkar Histamine in the regulation of wakefulness Sleep Med. Rev. 15 2011 65 74
76. 3 receptors and sleep-wake regulation J. Pharmacol. Exp. Ther. 336 2011 17 23
77. E.M. Ko et al. Wake-related activity of tubermammillary neurons in rats Brain Res. 992 2003 220 226
78. S. Morisset et al. High constitutive activity of native H3 receptors regulates histamine neurons in brain Nature 408 2000 860 864
79. 3 receptor as a novel therapeutic target for vigilance and sleep-wake disorders Biochem. Pharmacol. 73 2007 1157 1171
80. Z.L. Huang Altered sleep-wake characteristics and lack of arousal response to H3 receptor antagonist in H1 receptor knockout mice Proc. Natl. Acad. Sci. U. S. A. 103 2006 4687 4692
81. 3 antagonists for the treatment of cognitive disorders and Alzheimer's disease J. Pharmacol. Exp. Ther. 336 2011 38 46
82. A. Jucaite et al. AZD5213: a novel histamine H3 receptor antagonist permitting high daytime and low nocturnal H3 receptor occupancy, a PET study in human subjects Int. J. Neuropsychopharmacol. 16 2013 1231 1239
83. J-C. Schwartz The histamine H3 receptor: from discovery to clinical trials with pitolisant Br. J. Pharmacol. 163 2011 713 721
84. Y. Dauvilliers et al. Pitolisant versus plaebo or modafinil in patients with narcolepsy: a double-blind, randomised trial Lancet Neurol. 12 2013 1068 1075
85. M.J. Gemkow et al. The histamine H3 receptor as a therapeutic target for CNS disorders Drug Discov. Today 14 2009 9 10